Distribution and clinical association of plasma soluble ST2 during the development of type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 118, Issue , 2016, Pages 140-145

  Lin, Ya Hui ^a   Zhang, Rong Cheng ^a   Hou, Li Bo ^b   Wang, Kai Juan ^a   Ye, Zhong Ni ^a   Huang, Tao ^a   Zhang, Jian ^a   Chen, Xi ^a   Kang, Jin Suo ^a  

^a FUWAI HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Atherosclerosis; Prediabetes; sST2; Type 2 diabetes

Indexed keywords

GLUCOSE; BIOLOGICAL MARKER; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BIOASSAY; CONTROLLED STUDY; DISEASE ASSESSMENT; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SMOKING; BLOOD; DISEASE COURSE; MIDDLE AGED; RISK;

AGED; BIOMARKERS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; MALE; MIDDLE AGED; PREDIABETIC STATE; RISK;

EID: 84976568361     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.06.006     Document Type: Article

References (28)

1. [1] Schmitz, J., Owyang, A., Oldham, E., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:5 (2005), 479–490.
2. [2] Kakkar, R., Lee, R.T., The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discovery 7:10 (2008), 827–840.
3. [3] Mueller, T., Jaffe, A.S., Soluble ST2–analytical considerations. Am J Cardiol 115:7 Suppl (2015), 8B–21B.
4. [4] Peters, A., Epidemiology: air pollution and mortality from diabetes mellitus. Nat Rev Endocrinol 8:12 (2012), 706–707.
5. [5] Unger, J., Parkin, C.G., Type 2 diabetes: an expanded view of pathophysiology and therapy. Postgrad Med 122:3 (2010), 145–157.
6. [6] Miller, A.M., Asquith, D.L., Hueber, A.J., et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res 107:5 (2010 Sep 3), 650–658.
7. [7] Coglianese, E.E., Larson, M.G., Vasan, R.S., et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the framingham heart study. Clin Chem 58:12 (2012), 1673–1681.
8. [8] Miller, A.M., Purves, D., McConnachie, A., et al. Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes?. PLoS One, 7(10), 2012, e47830.
9. [9] Caporali, A., Meloni, M., Miller, A.M., et al. Soluble ST2 is regulated by p75 neurotrophin receptor and predicts mortality in diabetic patients with critical limb ischemia. Arterioscler Thromb Vasc Biol 32:12 (2012 Dec), e149–e160.
10. [10] Fousteris, E., Theodosis-Georgilas, A., Chantanis, S., et al. Head-to-head comparison of 2 inflammatory biomarkers for the long-term prediction of left ventricular diastolic dysfunction in type 2 diabetes patients: soluble ST2 versus hs-CRP. Int J Cardiol 174:3 (2014), 811–812.
11. [11] Fousteris, E., Melidonis, A., Panoutsopoulos, G., et al. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc Diabetol, 10, 2011, 101.
12. [12] Titov, V.N., Shiriaeva, Iu.K., Arteriolosclerosis and atherosclerosis. Pathology of the distal and proximal arterial bed. Pathogenesis of diabetic microangiopathy. Klin Lab Diagn 4 (2011), 3–14.
13. [13] Gao, Y., Lu, B., Sun, M.L., et al. Comparison of atherosclerotic plaque by computed tomography angiography in patients with and without diabetes mellitus and with known or suspected coronary artery disease. Am J Cardiol 108:6 (2011), 809–813.
14. [14] American Diabetes A. Standards of medical care in diabetes-2015 abridged for primary care providers. Clinical diabetes: a publication of the American Diabetes Association. 2015 33(2): pp. 97–111.
15. [15] Badea, R., Seicean, A., Diaconu, B., et al. Contrast-enhanced ultrasound of the pancreas–a method beyond its potential or a new diagnostic standard?. J Gastrointestin Liver Dis 18:2 (2009), 237–242.
16. [16] American College of Cardiology Foundation Task Force on Expert Consensus D, Mark DB, Berman DS, et al. ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010 121(22): pp. 2509–2543.
17. [17] Dieplinger, B., Januzzi, J.L. Jr., Steinmair, M., et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma–the presage ST2 assay. Clinica Chim Acta Int J Clin Chem 409:1–2 (2009), 33–40.
18. [18] Mihic, M., Modi, P., Metabolic syndrome–risk factors for atherosclerosis and diabetes. Curr Diabetes Rev 4:2 (2008), 122–128.
19. [19] Dhillon, O.S., Narayan, H.K., Quinn, P.A., et al. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with global registry of acute coronary events risk scoring and NT-proBNP. Am Heart J 161:6 (2011), 1163–1170.
20. [20] Kohli, P., Bonaca, M.P., Kakkar, R., et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 58:1 (2012 Jan), 257–266.
21. [21] Sabatine, M.S., Morrow, D.A., Higgins, L.J., et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117:15 (2008), 1936–1944.
22. [22] Fejfar, T., Safka, V., Jirkovsky, V., et al. Diabetes mellitus and the liver cirrhosis. Vnitr Lek 57:4 (2011), 368–371.
23. [23] Sattar, N., Scherbakova, O., Ford, I., et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 53:11 (2004), 2855–2860.
24. [24] Wannamethee, S.G., Shaper, A.G., Lennon, L., et al. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 28:12 (2005), 2913–2918.
25. [25] Abbasi, A., Bakker, S.J., Corpeleijn, E., et al. Liver function tests and risk prediction of incident type 2 diabetes: evaluation in two independent cohorts. PLoS One, 7(12), 2012, e51496.
26. [26] Trajkovic, V., Sweet, M.J., Xu, D., T1/ST2–an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev 15:2–3 (2004), 87–95.
27. [27] Stampalija, T., Romero, R., Korzeniewski, S.J., et al. Soluble ST2 in the fetal inflammatory response syndrome: in vivo evidence of activation of the anti-inflammatory limb of the immune response. J Matern Fetal Neonatal Med 26:14 (2013), 1384–1393.
28. [28] Miller, A.M., Xu, D., Asquith, D.L., et al. IL-33 reduces the development of atherosclerosis. J Exp Med 205:2 (2008 Feb 18), 339–346.